Blog

Aren Karapetyan: New study on nasopharyngeal carcinoma shows improved outcomes with Nedaplatin

Photo from Aren Karapetyan/LinkedIn

Sep 27, 2024, 16:51

Aren Karapetyan: New study on nasopharyngeal carcinoma shows improved outcomes with Nedaplatin

Aren Karapetyan, Oncology Resident at Yerevan State Medical University, shared the following on LinkedIn:

“New study on nasopharyngeal carcinoma shows that fatigue and appetite loss during chemoradiotherapy significantly increase the risk of distant metastasis. Nedaplatin proved as effective as Cisplatin, with better tolerance and less toxicity.”

Joint modeling of longitudinal health-related quality of life during concurrent chemoradiotherapy period and long-term survival among patients with advanced nasopharyngeal carcinoma

Authors: Ji-Bin Li, Shan-Shan Guo, Ting Liu, Zhuo-Chen Lin, Wei-Jie Gong, Lin-Quan Tang, Ling Guo, Hao-Yuan Mo, Hai-Qiang Mai & Qiu-Yan Chen.

Source: Aren Karapetyan/LinkedIn

appetite loss Aren Karapetyan cancer chemoradiotherapy Cisplatin distant metastasis fatigue nasopharyngeal carcinoma Nedaplatin OncoDaily Oncology toxicity treatment tolerance

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Special Coverage